Patterns and management outcomes of urticaria in a tertiary hospital setting
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261663Keywords:
Chronic urticaria, Chronic spontaneous urticaria, UAS7, Antihistamine up-dosingAbstract
Background: Urticaria is a common pruritic wheal disorder, with or without angioedema, classified as acute or chronic. Chronic urticaria often recurs, impairs quality of life, and requires stepwise antihistamine-based treatment. However, local data on disease patterns and treatment outcomes in Bangladesh remain limited.
Methods: This observational study was conducted at the Department of Dermatology and Venereology, Railway General Hospital, CRB, Chittagong, Bangladesh, from January to December 2025. A total of 125 consecutive patients with urticaria were enrolled. Cases were classified as acute or chronic, with chronic urticaria further categorized into chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or mixed. Disease severity was assessed using UAS7. Treatment patterns and 4-week outcomes were recorded.
Results: Of the patients, 58.4% were female and 51.2% were aged 20-39 years. Chronic urticaria accounted for 63.2% of cases, predominantly CSU (55.2%). Angioedema occurred in 30.4%, and generalized wheals in 73.6%. Triggers were unidentified in 32.0%, while stress (41.6%), foods (26.4%), drugs (22.4%), and infections (19.2%) were common. Atopy was present in 39.2% and thyroid disease in 12.0%. Moderate-to-severe UAS7 was observed in 54.4%, with 47.2% reporting sleep disturbance. All patients received second-generation antihistamines; 44.8% required up-dosing and 32.8% received short-term steroids. At 4 weeks (92.0% follow-up), 64.4% achieved complete or well-controlled status, 15.7% relapsed, and 12.0% reported adverse effects.
Conclusions: Chronic urticaria, mainly CSU, predominated with moderate-to-severe activity at presentation. Most patients achieved symptom control within 4 weeks using stepwise antihistamine therapy, though up-dosing was frequently required and some remained uncontrolled or relapsed.
References
Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer‐Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414.
Gonçalo M, Gimenéz‐Arnau A, Al‐Ahmad M, Ben‐Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Brit J Dermatol. 2021;184(2):226-36.
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.
Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta‐analysis. Allergy. 2020;75(2):423-32.
Hasan MK, Haque E, Al Miraj AK, Nath SK, Sarker SC. Skin diseases pattern in a tertiary care Hospital, developing countries like Bangladesh. Contact Dermatitis. 2024;77:5.
Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Eng J Med. 2013;368(10):924-35.
Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Experime Allergy. 2009;39(6):777-87.
Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient-Patient-Centered Outcomes Res. 2015;8(6):551-8.
Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality of life in Korean patients. Ann Dermatol. 2009;21(3):226-9.
Noor SF, Jannat S, Khan SI, Azzad MA. Clinical Association of Anti-TPO in Patients with Chronic Urticaria. J Rangpur Med College. 2023;8(2):29-33.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-66.
Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic urticaria: a Swedish registry-based cohort study on population, comorbidities and treatment characteristics. Acta Dermato-Venereologica. 2022;102:737.
Kolkhir P, Pogorelov D, Darlenski R, Caminati M, Tanno LK, Le Pham D, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11:14.
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez‐Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real‐world evidence from ASSURE‐CSU. Allergy. 2017;72(12):2005-16.
Sussman G, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez‐Arnau A, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE‐CSU. Allergy. 2018;73(8):1724-34.
Maurer M, Giménez-Arnau A, Ensina LF, Chu CY, Jaumont X, Tassinari P. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organization J. 2020;13(9):100460.
Wagner N, Zink A, Hell K, Reinhardt M, Romer K, Hillmann E, et al. Patients with chronic urticaria remain largely undertreated: results from the DERMLINE online survey. Dermatol Therapy. 2021;11(3):1027-39.
Reeshma J, Mariyath OK, Narayan KD, Devi K, Ajithkumar K. Quality of Life and Perceived Stress in Chronic Spontaneous Urticaria: Counting the Burden. Indian Dermatol Online J. 2024;15(3):460-3.
Tienforti D, Di Giulio F, Spagnolo L, Castellini C, Totaro M, Muselli M, et al. Chronic urticaria and thyroid autoimmunity: A meta-analysis of case–control studies. J Endocrinolog Investigat. 2022;45(7):1317-26.
Wang X, Liu LJ, Li LF, Shi XD, Shen YW. Clinical features of urticaria: results from a hospital-based multicenter study in China. Front Med. 2022;9:899857.
Chu CY, Al Hammadi A, Agmon-Levin N, Atakan N, Farag A, Arnaout RK, et al. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-antihistamines in Asia, Middle-East and Africa: results from the AWARE-AMAC study. World Allergy Organiz J. 2020;13(4):100117.
Downloads
Published
How to Cite
Issue
Section
